Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: MicardisPlus®; Drug: Micardis®

Study type: Observational

Funder types: Industry

Identifiers

NCT02262611

502.428

502.429, 502.430, 502.431 (Other Identifier)

Details and patient eligibility

About

Study to obtain long-term data on effects, safety and tolerability in routine medical practice and to investigate the potential of telmisartan to prevent secondary organ damage

Enrollment: 266 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients of both gender aged >=18 admitted to a hospital due to insufficiently controlled essential hypertension.

No additional selection criteria have to be considered. Treatment was at the discretion of the physician following the summary of product information for Micardis® and MicardisPlus®

Exclusion criteria

• not applicable

Trial design

266 participants in 4 patient groups

Hypertension patients - Pneumology

Treatment:

Drug: MicardisPlus®

Drug: Micardis®

Hypertension patients - Cardiology

Treatment:

Drug: MicardisPlus®

Drug: Micardis®

Hypertension patients - Nephrology

Treatment:

Drug: MicardisPlus®

Drug: Micardis®

Hypertension patients - Diabetology

Treatment:

Drug: MicardisPlus®

Drug: Micardis®